News | November 30, 2022
Gland Pharma to buy French pharma company Cenexi
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
This is the ninth Covid-19 vaccine approved in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)